ShockWave Medical stock (US8130281086): Intravascular lithotripsy leader in cardiovascular devices

ShockWave Medical has established itself as a key player in the medical device sector, specializing in intravascular lithotripsy (IVL) technology. This innovative approach uses sonic pressure waves to disrupt calcified plaques, enabling safer treatment of arterial calcifications during procedures like percutaneous coronary intervention (PCI) and peripheral artery interventions. The technology addresses a critical need in patients with severe calcium buildup, where traditional methods often fall short.

The stock traded at approximately 282.66 USD on Nasdaq as of its last reported close before acquisition developments, according to Yahoo Finance as of 03/18/2024. US investors track ShockWave Medical for its role in advancing cardiovascular care, a sector vital to the aging US population.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

ShockWave Medical: core business model

ShockWave Medical's business centers on its proprietary intravascular lithotripsy platform, which combines a balloon catheter with sonic wave emitters. This allows physicians to fracture calcium without excessive vessel trauma, improving procedural outcomes. The company generates revenue primarily from selling disposable catheters, generators, and support consoles to hospitals and cath labs worldwide. According to the company's investor relations site, the IVL system has received FDA approval for coronary and peripheral use, driving adoption in high-volume US centers ShockWave Medical IR as of 2024.

The model emphasizes recurring revenue from single-use catheters paired with durable equipment sales. ShockWave targets interventional cardiology and vascular surgery markets, where calcium modification represents an unmet need. Clinical data from trials like Disrupt CAD showed high procedural success rates, supporting reimbursement and market penetration.

Main revenue and product drivers for ShockWave Medical

Revenue stems from the Shockwave IVL System, including products like the Shockwave IVL Catheter with integrated generator. In coronary applications, it treats calcified lesions in PCI, while peripheral versions address iliac, femoral, and below-the-knee arteries. The company reported Q4 2023 revenue of 119.0 million USD, up 75% year-over-year, per its Q4 2023 earnings release as of 02/08/2024. US sales dominate, reflecting strong demand in Medicare-covered procedures.

Key drivers include expanding indications, international growth, and physician training programs. Reimbursement codes from CMS enhance accessibility for US providers, fueling catheter utilization rates.

Industry trends and competitive position

The cardiovascular device market faces rising demand from coronary artery disease and peripheral artery disease, exacerbated by diabetes and aging demographics in the US. ShockWave's IVL differentiates from atherectomy devices and specialty balloons by offering a lower risk of perforation. Competitors include Boston Scientific and Medtronic, but ShockWave holds a first-mover advantage in sonic lithotripsy, with over 50,000 cases treated globally by early 2024.

Why ShockWave Medical matters for US investors

Listed on Nasdaq, ShockWave Medical provides US investors exposure to medtech innovation addressing CMS-reimbursed procedures. Its technology aligns with value-based care trends, potentially lowering long-term costs for complex PCI cases. The firm's US headquarters in Santa Clara, CA, and focus on domestic sales underscore relevance amid healthcare spending growth projected by S&P Global.

Conclusion

ShockWave Medical has built a strong position in intravascular lithotripsy, with robust revenue growth and clinical validation supporting its market role. While acquisition by Johnson & Johnson in 2024 marked a significant milestone, the underlying technology continues to influence cardiovascular treatments. Investors monitor ongoing developments in this dynamic medtech space.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.